SkinBioTherapeutics PLC (LON:SBTX) has been granted a first patent in Australia for Skinbiotix, its probiotic skin health platform.
The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease and runs until 15 March 2033, the company said in a statement on Friday.
READ: SkinBioTherapeutics technology gets double green light - next stop human studies
Catherine O'Neill, SkinBioTherapeutics’ chief executive, said: "The Australian skincare market is a key global market.
“The progression and successful grant of the first national patent to emerge from the company's Skinbiotix patent family underpins the commercial potential worldwide.
"This is a step forward in preparing for human trials, which are scheduled for 2018."